Applying of 13C-MDT in early diagnosis of non-alcoholic fatty liver disease
No. 2-3 (2022), HEPATOLOGY
No. 2-3 (2022)

Applying of 13C-MDT in early diagnosis of non-alcoholic fatty liver disease

HEPATOLOGY
Published October 4, 2022
O.Ye. Sklyarova
Львівський національний медичний університет ім. Данила Галицького
T.M. Solomenchuk
Львівський національний медичний університет ім. Данила Галицького
K.Ya. Pokhodai
КНП «Перше територіальне медичне об’єднання м. Львова»
I.B. Kolomiiets
КНП «Четверта міська поліклініка м. Львова»
pdf (Українська)

Keywords

13C-metacetin breath test (13C-MDT), non-alcoholic fatty liver disease (NAFLD)

How to Cite

Sklyarova, O., Solomenchuk, T., Pokhodai, K., & Kolomiiets, I. (2022). Applying of 13C-MDT in early diagnosis of non-alcoholic fatty liver disease. The Practitioner, (2-3), 91-95. Retrieved from https://plr.com.ua/index.php/journal/article/view/724
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

The aim of the study was to evaluate the dynamics of changes in 13C-metacetin breath test in patients with non-alcoholic fatty liver disease and healthy individuals. Material and methods. 30 people with hepatic steatosis and 17 apparently healthy volunteers were examined. The complete clinical examination included anthropometric characteristics (height, body weight, body mass index), determination of hepatic transaminases, lipid profile, ultrasound investigation of the liver and 13C-metacetin breath test. Results. At careful inspection of patients with NAFLD overweight or obesity, signs of a metabolic syndrome, dyslipidemia, increase in concentration of ALT and AST are most often found. According to the results of ultrasound diagnostic in 80% of the examined patients with steatosis showed hepatomegaly, hyperechogenicity and heterogeneity of liver structure. According to the results of 13C-MDT, it was found that the rate of metabolism is maintained at a high level in apparently healthy individuals, which provides sufficient accumulation of 13C-metacetin and corresponds to approximately 100% of functioning hepatocytes. Under steatosis, the slowing of the metabolic rate and, accordingly, a significant reduction in the cumulative dose is due to a reduction in the functional activity of hepatocytes to 30-40 min instead of 60 min compared to apparently healthy individuals. Conclusions. The diagnostic value of 13C-MDT is in non-invasive dynamic assessment of metabolic rate and changes in liver metabolic capacity in vivo at an early stage of NAFLD. It was found that in the presence of hepatic steatosis there is a slowing of metabolic rate and a reliable reduction of the cumulative dose, due to reduced functional activity of hepatocytes. The above changes in test parameters allow to estimate the condition of the liver and are reasonable causes to recommend such patients to make lifestyle modifications and prescribe early treatment. Using of 13C-MDT in medical practice will deepen the knowledge of scientists on the pathogenesis of steatosis, improve its diacrisis and approaches to treatment.

pdf (Українська)

References

1. Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, Bass NM. Nonalcoholic Steatohepatitis Clinical Research Network. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012 Sep;56(3):943-51. doi: 10.1002/hep.25772. Epub 2012 Jul 26. PMID: 22505194; PMCID: PMC3407289.
2. Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS. Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 Mar 5;73(8):948-963. doi: 10.1016/j.jacc.2018.11.050. PMID: 30819364.
3. Chinnadurai R, Ritchie J, Green D, Kalra PA. Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease. Nephrol Dial Transplant. 2019 Mar 1;34(3):449-457. doi: 10.1093/ndt/gfx381. PMID: 29390103.
4. Степанов ЮМ. Результати обсерваційного перехресного дослідження PRELID 2 (2015–2016). Частина 1. Поширеність неалкогольної жирової хвороби печінки, характеристика супутньої патології, метаболічного синдрому та його окремих критеріїв у пацієнтів, які звертаються до терапевтів і гастроентерологів в Україні. Гастроентерол. 2019;53(1):26-33. doi:10.22141/2308-2097.53.1.2019.163454.
5. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011 Jan;140(1):124-31. doi: 10.1053/j.gastro.2010.09.038. Epub 2010 Sep 19. PMID: 20858492.
6. Герок В, Блюм ХЕ. Заболевания печени и желчевыделительной системы. М.: МЕДпресс-информ, 2009:199.
7. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. American Association for the Study of Liver Diseases; American College of Gastroenterology; American Gastroenterological Association. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012 Jun;107(6):811-26. doi: 10.1038/ajg.2012.128.
8. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016 Jun;64(6):1388-402. doi: 10.1016/j.jhep.2015.11.004. Epub 2016 Apr 7. PMID: 27062661.
9. Стаценко МЕ, Туркина СВ, Косивцова МА, Шилина НН. Неинвазивная диагностика неалкогольной жировой болезни печени: простые инструменты уже в руках практического врача. Вестник ВолгГМУ. 2019;2(70):134-139.
10. Musialik J, Jonderko K, Kasicka-Jonderko A, Buschhaus M. (13) CO2 breath tests in non-invasive hepatological diagnosis. Prz Gastroenterol. 2015;10(1):1-6. DOI: 10.5114/pg.2014.47501. Epub 2015 14 січня. PMID: 25960807; PMCID: PMC4411407.
11. Modak AS. Stable isotope breath tests in clinical medicine: a review. J Breath Res. 2007 Sep;1(1):014003. doi: 10.1088/1752-7155/1/1/014003. Epub 2007 Jul 11. PMID: 21383429.
12. Lacroix M, Mosora F, Pontus M, Lefebvre P, Luyckz A, Lopez-Habib G. Glucose naturally labeled with carbon-13: use for metabolic studies in man. Science. 1973 Aug 3;181(4098):445-6. doi: 10.1126/science.181.4098.445. PMID: 4718109.
13. Krumbiegel P, Günther K, Faust H, Möbius G, Hirschberg K, Schneider G. Nuclear medicine liver function tests for pregnant women and children. 1. Breath Tests with 14C-methacetin and 13C-methacetin. Eur. J. Nucl. Med. 1985;10(3-4):129-33.
14. Petrolati A, Festi D, De Berardinis G, Colaiocco-Ferrante L, Di Paolo D, Tisone G, Angelico M. 13C-methacetin breath test for monitoring hepatic function in cirrhotic patients before and after liver transplantation. Aliment Pharmacol Ther. 2003 Oct 15;18(8):785-90. doi: 10.1046/j.1365-2036.2003.01752.x. PMID: 14535871.
15. Hofmann AF. The role of breath tests in liver functioning testing. In: Perri, F, Andriulli, A, eds. Clinical Application of Breath Tests in Gastroenterology and Hepatology. Rome: International University Press, 1998:47-51.

Downloads

Download data is not yet available.

Most read articles by the same author(s)